Clinical Trials Browser

Phase 2 × Somatostatinoma × sapanisertib × Clear all

NCT02893930 2023-10-17

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Phase 2 Completed

13 enrolled 9 charts

Somatostatinoma